Takeda's zasocitinib has shown positive results in a phase III trial for psoriasis, with reports indicating it outperformed Bristol Myers' Sotyktu. The trial's endpoints were met, with some outlets describing zasocitinib's performance as "best-in-class". The outcome of the trial suggests a potential advancement in treatment for plaque psoriasis.